PubMed Health⌕ Search

PubMed · 9320480

Apparent water permeability as a physiological parameter in crustaceans

Abstract

This article reviews the use of apparent water permeability (AWP) calculated from measurements of isotope-labelled water flux as a physiological estimate of whole-body water permeability in aquatic invertebrates. The rationale and practices of AWP calculations are described in an Appendix. AWP calculations have provided a wealth of information. However, the validity of the method and therefore also of the information obtained have been questioned. Consequently, the use of AWP data in discussions of osmotic and fluid homeostatic questions in aquatic invertebrates is limited. This article reviews three decades of published experiments in which measurements of isotope-labelled water fluxes were used to estimate water permeability in aquatic invertebrates. Data on 24 species of arthropod, most of them decapod crustaceans, are presented. The combined data indicate that the results obtained by different investigators on the same species show good agreement, even though different tracers and experimental methods have been applied. When available, results from other kinds of studies were used to evaluate the results obtained using the AWP measurements. The various results demonstrate that AWP is influenced not only by natural environmental factors, such as salinity and temperature, and by anthropogenic factors, such as potentially toxic trace metals, but that it is also regulated by intrinsic factors, such as ecdysis and life cycle stage. The results obtained can often be explained as effects of components of the habitat of the animal. Accordingly, studies on variations in AWP contribute to our understanding of the different physiological strategies used by species living in a changing environment. We conclude that calculations of AWP offer reliable, relevant physiological data in a range of crustacean species, as long as methodological limitations and uncertainties are kept in mind. In addition, we propose some possible new ways of applying AWP calculations to marine invertebrates other than crustaceans. A major part of this review describes results already obtained for the shore crab Carcinus maenas as this species is probably the animal on which most work has been carried out. We suggest topics for future work on this species and review the possibility of using AWP in C. maenas as a biomarker of metal exposure.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Rasmussen, O Andersen. 1996. Apparent water permeability as a physiological parameter in crustaceans. https://doi.org/10.1242/jeb.199.12.2555

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗